Key regions: France, India, United Kingdom, South Korea, Japan
The Multiple Sclerosis Drugs market in Armenia has been experiencing steady growth in recent years.
Customer preferences: Armenian customers tend to prefer drugs that have been approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). They also look for drugs that have been proven to be effective in clinical trials and have minimal side effects. As a result, pharmaceutical companies that have drugs approved by these regulatory bodies are more likely to succeed in the Armenian market.
Trends in the market: One of the major trends in the Multiple Sclerosis Drugs market in Armenia is the increasing availability of disease-modifying therapies (DMTs). These drugs are designed to slow down the progression of the disease and reduce the frequency and severity of relapses. Another trend is the growing use of oral DMTs, which are more convenient for patients than injectable DMTs. Additionally, there is a trend towards personalized medicine, with pharmaceutical companies developing drugs that target specific subtypes of multiple sclerosis.
Local special circumstances: Armenia has a relatively small population, which means that the market for Multiple Sclerosis Drugs is limited. However, the country has a high prevalence of multiple sclerosis compared to other countries in the region. This means that there is a significant unmet need for effective treatments for the disease. Additionally, the Armenian government provides free healthcare to its citizens, which means that many patients are able to access Multiple Sclerosis Drugs through the state healthcare system.
Underlying macroeconomic factors: Armenia is a developing country with a growing economy. However, the country has a relatively low GDP per capita compared to other countries in the region. This means that many patients may struggle to afford high-priced drugs. Additionally, the Armenian pharmaceutical market is relatively small, which means that pharmaceutical companies may be hesitant to invest in the country. However, the government has been taking steps to improve the regulatory environment and attract foreign investment, which could lead to increased competition and lower prices for Multiple Sclerosis Drugs in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
